Cagrilintide (AM833) is a stable, lipidated, long-acting analogue of amylin, a pancreatic hormone. Native amylin has a strong tendency to form amyloid fibrils, which makes it a difficult starting point for drug design; the structure-activity work that led to cagrilintide was published in 2021. It is a non-selective agonist of the amylin receptors (AMY1R, AMY2R and AMY3R, which are heterodimers of the calcitonin receptor with receptor activity-modifying proteins) and of the calcitonin receptor itself. Research has spanned receptor pharmacology, cryo-electron microscopy, rodent studies of energy balance and registered clinical trials.